Related by context. All words. (Click for frequent words.) 74 BRAF mutation 74 EGFR mutations 72 KRAS mutations 72 KRAS mutation 69 HER2 receptor 69 FLT3 68 KRAS status 68 K ras mutations 67 EGFR inhibitors 67 K ras 67 mCRC patients 67 gefitinib 67 KRAS gene 66 HER2 positive cancers 66 nonsmall cell lung cancer 66 BRAF V#E mutation 66 estrogen receptor ER 66 KRAS wild 66 GISTs 66 micrometastases 66 T#I [002] 66 NSCLC 66 BRAF mutations 65 EGFR 65 EGFR activating mutations 65 T#I mutation 65 BRCA mutations 65 hormone receptor positive 65 mutated K ras 64 EGFR tyrosine kinase inhibitors 64 Epidermal Growth Factor Receptor 64 gefitinib Iressa 64 KRAS 64 recurrent NSCLC 64 Squamous 64 imatinib Gleevec 64 cancer mCRC 64 TGFBR1 * 6A 64 breast carcinomas 64 PCa 64 pancreatic adenocarcinoma 64 dasatinib 64 imatinib resistance 64 sorafenib Nexavar 64 trastuzumab Herceptin ® 64 mutated KRAS gene 64 mRCC 64 basal cell carcinoma BCC 64 medullary thyroid cancer 64 Her2 64 EpCAM 64 GBM tumors 63 SERMs 63 HNSCC 63 endocrine therapies 63 Imatinib 63 mutated KRAS 63 HER2 gene 63 HER2 positive tumors 63 chemopreventive agent 63 K ras gene 63 HER2 positive 63 colorectal carcinoma 63 EGFR inhibitor 63 M#V mutation 63 liver metastases 63 poorer prognosis 63 advanced adenomas 63 Zolinza 63 PARP inhibitor 63 adenocarcinomas 63 BCR ABL mutations 63 hepatocellular carcinoma HCC 63 IGF IR 63 HBsAg 63 castration resistant prostate cancer 63 EGFr 63 colorectal tumors 63 metastatic neuroendocrine tumors 63 B7 H3 63 MAGE A3 63 breast carcinoma 63 distant metastases 63 urothelial carcinoma 63 Gleevec resistant 63 vandetanib 63 distant metastasis 63 prostate cancer CaP 63 metastatic RCC 62 WT1 62 genotypic resistance 62 gastrointestinal stromal tumors 62 gastric adenocarcinoma 62 EGFRvIII 62 EGFR gene 62 Her2/neu 62 metastatic renal cell carcinoma 62 MGUS 62 standard chemotherapy regimens 62 mutated BRAF gene 62 HER2 positive metastatic breast 62 gastric cancers 62 olaparib 62 iniparib 62 HPV# 62 mutant KRAS 62 ADPKD 62 Cytoxan 62 Gefitinib 62 EGFR expression 62 BCR ABL 62 neuroblastoma tumors 62 EGFR mutation status 62 androgen independent 62 prognostic markers 62 relapsed ovarian cancer 62 epithelial tumors 62 BRCA1 mutation 62 prostate cancer CRPC 62 carcinoid 62 prostate carcinoma 62 HER2 expression 62 pCR 62 tyrosine kinase inhibitors 62 histological subtype 62 alkylating agents 62 lymph node metastases 62 K RAS 62 flavopiridol 62 premalignant lesions 62 ERBB2 62 lung adenocarcinoma 62 MET amplification 62 NNRTI resistance 62 EGFR TKI 62 EGFR protein 62 ovarian carcinoma 62 estrogen receptor negative 62 receptor tyrosine kinase inhibitor 62 HER2 overexpression 62 hypermethylated 62 malignant pleural mesothelioma 62 endometrial cancers 62 SCCHN 62 trastuzumab Herceptin 62 ApoE4 62 antitumor effect 62 NPM1 62 relapsed SCLC 62 TTR gene 62 EGFR mutant 62 prognostic indicator 62 erlotinib Tarceva ® 62 activating mutations 62 B CLL 62 germline mutations 61 chemoresistant 61 K#R [002] 61 non squamous NSCLC 61 Vectibix 61 HER2 amplification 61 sentinel nodes 61 resectable 61 erlotinib 61 bicalutamide 61 renal cell carcinomas 61 promoter methylation 61 operable breast cancer 61 poor metabolizers 61 neoadjuvant therapy 61 MAGE A3 ASCI 61 BRCA mutation 61 mapatumumab 61 alkylating agent 61 taxane chemotherapy 61 mTOR inhibitors 61 HER2/neu 61 EGFR mutation positive 61 BRAF gene 61 K ras mutation 61 HGPIN 61 tumor subtypes 61 mucinous 61 cisplatin resistant 61 differentiated thyroid 61 Pemetrexed 61 castrate resistant 61 castration resistant 61 metastatic melanomas 61 cyclin E 61 prognostic marker 61 Everolimus 61 EGFR receptor 61 TOP2A 61 gemcitabine Gemzar 61 PKCi 61 XmAb# 61 hepatocellular carcinomas 61 KIT mutations 61 ABCB1 61 TKI therapy 61 dasatinib Sprycel 61 locoregional 61 advanced NSCLC 61 Epstein Barr virus EBV 61 VEGF inhibitors 61 prostate cancer PCa 61 FGFR2 61 metastatic gastric 61 tumor necrosis 61 eIF 4E 61 selective modulator 61 axillary lymph nodes 61 metastatic colorectal 61 Ceflatonin 61 androgen deprivation 61 gastrointestinal stromal tumors GIST 61 antiproliferative effects 61 ERCC1 61 pancreatic cancers 61 KRAS oncogene 61 K#N 61 hormone receptor negative 61 bevacizumab Avastin 61 Xanafide 61 trastuzumab 61 imatinib 61 DFMO 61 histologies 61 gemcitabine chemotherapy 61 superficial bladder cancer 61 LRAT 61 relapsed MM 61 calcineurin inhibitors 61 cetuximab 61 ErbB2 positive 61 anti angiogenic agents 60 malignant lesions 60 Torisel 60 prognostic factor 60 GIST tumors 60 colorectal cancer CRC 60 estrogen receptors 60 H pylori 60 xenograft tumors 60 CYP#C# [001] 60 posaconazole 60 neoplasias 60 breast cancer subtypes 60 Erlotinib 60 recurrent glioblastoma multiforme 60 metastatic lesions 60 mycophenolate mofetil 60 imatinib Gleevec ® 60 renal carcinoma 60 JAK2 mutation 60 EUS FNA 60 Tavocept 60 HBeAg 60 EGF receptor 60 colorectal carcinomas 60 pertuzumab 60 adenocarcinoma 60 HCV infection 60 pegylated liposomal doxorubicin 60 Velcade bortezomib 60 hormone refractory 60 AGTR1 60 hepatoma 60 temsirolimus 60 GSTP1 60 nucleoside analogue 60 myeloproliferative diseases 60 Stat5 60 HCV replicon 60 mesotheliomas 60 axitinib 60 IFN beta 60 p# mutations 60 squamous histology 60 gastrointestinal stromal tumors GISTs 60 Herceptin trastuzumab 60 NSCLC tumors 60 CLL cells 60 MSH2 60 TNF α 60 carcinoids 60 estrogen receptor 60 HER2 60 MetMAb 60 VKORC1 60 endostatin 60 mutant BRAF 60 neuroendocrine tumors 60 KRAS mutant tumors 60 metastatic colorectal cancer 60 HER2 negative 60 colon tumors 60 lymph node metastasis 60 gemcitabine carboplatin 60 CIN3 60 basal cell nevus syndrome 60 epithelial ovarian cancer 60 lung metastasis 60 sarcosine 60 adjuvant radiotherapy 60 BRCA deficient 60 colorectal polyp 60 BRAF V# mutation 60 cetuximab Erbitux 60 premalignant 60 mutant allele 60 heavily pretreated 60 paricalcitol 60 adjuvant therapy 60 p# biomarker 60 molecular subtypes 60 PARP inhibitors 60 erlotinib Tarceva 60 recurrent ovarian cancer 60 malignant transformation 60 FGFR1 60 cervical lesions 60 EGFR pathway 60 cisplatin chemotherapy 60 EBV infection 60 p# mutation 60 suppressor gene 60 nonmelanoma skin cancers 60 bone metastasis 60 IRESSA 60 azacytidine 60 PC3 cells 60 Surgical resection 60 sorafenib 60 vorinostat 60 HBeAg negative 60 IGF 1R 60 trans retinoic acid 60 ErbB2 60 Akt activation 60 HLA DR 60 VEGFR2 60 MGMT gene 60 myelofibrosis polycythemia vera 60 preclinically 60 carcinoembryonic antigen 60 HIV HCV coinfected 60 APOE e4 60 miRview ™ squamous 60 stage IIIB 60 pancreatic neuroendocrine tumors 60 rs# [002] 60 BRCA1 mutations 60 sorafenib tablets 60 lapatinib Tykerb 60 CYT# potent vascular disrupting 60 unresectable tumors 60 imatinib therapy 60 carcinoid tumors 60 Trastuzumab 60 systemic lupus erythematosus SLE 60 chlamydial infection 60 hormonal therapies 60 riociguat 60 intestinal metaplasia 60 BCG refractory 60 GSTM1 59 micrometastasis 59 MTHFR 59 breast tumors 59 mtDNA mutations 59 oral FTY# 59 biochemical recurrence 59 JAK inhibitors 59 serous ovarian cancer 59 carcinomas 59 cediranib 59 chlamydial 59 hepatocellular cancer 59 XELOX 59 AVASTIN 59 bevacizumab Avastin ® 59 TNFa 59 cMET 59 endometrial hyperplasia 59 HER2 neu 59 efalizumab 59 etoposide 59 myeloma cells 59 inhibitor RG# 59 lung tumors 59 idarubicin 59 mTOR inhibitor 59 JAK2 59 node metastases 59 squamous 59 Bortezomib 59 taxane therapy 59 complete cytogenetic response 59 receptor blocker 59 tumors 59 NRTIs 59 HCV genotypes 59 hematopoietic cells 59 skeletal metastases 59 CIN2 + 59 neuroendocrine cancers 59 Amrubicin 59 Neuvenge 59 glioma cells 59 neoadjuvant chemotherapy 59 Aflibercept 59 chemosensitivity 59 GPNMB 59 GnRH agonists 59 TPMT 59 cytokeratin 59 liver metastasis 59 CYP#D# genotype 59 pomalidomide 59 vimentin 59 gene amplification 59 contralateral breast 59 androgen receptor AR 59 situ CIS 59 estrogen receptor progesterone receptor 59 GRASPA ® 59 stage IIIb IV 59 HER2 + 59 chronic HBV infection 59 Dasatinib 59 PPARγ 59 antigen PSA 59 caspofungin 59 MAPK pathway 59 HRPC 59 malignant nodules 59 trabectedin 59 H. pylori eradication 59 CXCR4 59 interferon IFN 59 multidrug resistance 59 malignant ascites 59 BRCA2 gene mutation 59 seminoma 59 anti JCV antibodies 59 factor receptor EGFR 59 histologic diagnosis 59 CC genotype 59 metastatic tumors 59 bendamustine 59 invasive carcinoma 59 prostate cancers 59 imatinib resistant 59 RAS mutations 59 angiogenesis inhibitor 59 pDCs 59 adriamycin 59 glioblastoma tumors 59 RAR beta 59 KRAS mutant 59 EGFR TKIs 59 HER2 receptors 59 EGF receptors 59 CCR5 antagonist 59 colorectal liver metastases 59 Arranon 59 leukemic stem cells 59 HER2 positive breast cancer 59 urothelial bladder cancer 59 CBLC# 59 preoperative chemotherapy 59 renal tumors 59 decitabine 59 EGFR HER2 59 nilotinib 59 OGG1 59 cytotoxin 59 grade cervical intraepithelial 59 NNRTIs 59 metastatic prostate 59 INCB# [003] 59 OPAXIO 59 ADAM# 59 RRM1 59 HBV infection 59 entecavir 59 HGS ETR1 59 invasive ductal 59 genetic polymorphisms 59 syngeneic 59 fulvestrant 59 cagA 59 Bcr Abl 59 bladder cancers 59 adjuvant radiation 59 Hurthle cell 59 CsA 59 N. gonorrhoeae 59 fluvastatin 59 nodal metastasis 59 pheochromocytoma 59 sentinel lymph node biopsy 59 tamoxifen Nolvadex ® 59 noncancerous cells 59 LRP5 59 KRAS mutations occur 59 mutational status 59 pulmonary metastases 59 squamous cell histology 59 Gleevec imatinib 59 Hepatocellular Carcinoma HCC 59 CMV disease 59 locoregional recurrence 59 PARP inhibition 59 forskolin 59 Immunohistochemical analysis 59 IFN α 59 anti angiogenic agent 59 IDH2 59 flutamide 59 TNFalpha 59 fluoropyrimidine 59 endoxifen 59 EOquin 59 hepatocellular carcinoma 59 T#I mutant 59 NRTI resistance 59 MyVax R 59 Azedra 59 UGT#A# 59 hyperplastic 59 tumor histology 59 leukaemias 59 chemoresistance 59 FOLFOX4 59 anastrozole 59 nasopharyngeal carcinoma 59 pediatric malignancies 59 MIF protein 59 dexrazoxane 59 HCV genotype 59 NPM1 mutation 59 breast cancer metastasis 59 follicular lymphoma FL 59 HDAC inhibitors 59 cytostatic 58 talabostat 58 Li Fraumeni 58 Clusterin 58 sustained virologic response 58 anidulafungin 58 NAbs 58 occult metastases 58 tumorigenic 58 invasive carcinomas 58 PTPN# 58 CYP#C# [002] 58 renal toxicity 58 causal variants 58 Pertuzumab 58 NKT cells 58 IDH1 mutation 58 metastatic malignant melanoma 58 anthracyclines 58 platinum refractory 58 IDH1 58 CCR9 58 TP# mutations 58 alkaline phosphatase ALP 58 NKG2D 58 chronic lymphocytic leukemia CLL 58 G CSF 58 FLT3 ITD 58 medically inoperable 58 tumors GIST 58 advanced adenoma 58 GSTT1 58 pro angiogenic 58 HuLuc# 58 E. faecalis 58 lung carcinomas 58 peritoneal carcinomatosis 58 PDGF receptor 58 Leukemias 58 vemurafenib 58 tumor xenograft models 58 Avastin bevacizumab 58 chlorambucil 58 Raf MEK ERK 58 cell carcinomas 58 xenograft models 58 Aplidin 58 Bezielle 58 proteasome inhibitor 58 enzastaurin 58 familial pancreatic cancer 58 Vandetanib 58 Leydig cell 58 mutant p# 58 immunohistochemical analysis 58 leukemia CLL 58 platelet inhibitor 58 HER3 58 herpesviruses 58 pancreatic carcinoma 58 NF kB pathway 58 heterozygous 58 uveal melanoma 58 haematopoietic 58 unresectable 58 neoplasia 58 SNP rs# [001] 58 thalidomide Thalomid 58 TroVax ® 58 castrate resistant prostate cancer 58 atypical ductal hyperplasia 58 axillary nodes 58 Taxotere chemotherapy 58 prostate tumor 58 effector function 58 HER-2/neu 58 breast cancers 58 paclitaxel Taxol 58 HBeAg positive 58 neoplastic cells 58 Irinotecan 58 ALND 58 peritoneal cancer 58 metastatic lung cancer 58 pegfilgrastim 58 JAK3 58 intravenous bisphosphonates 58 FCGR3A 58 TKIs 58 TP# mutation 58 APTIVUS 58 GW# [003] 58 ixabepilone 58 refractory chronic myeloid 58 activating mutation 58 mCRC 58 survivin 58 MDM2 58 MYCN amplification 58 melanoma tumors 58 luteinizing hormone releasing 58 Aurora kinase 58 sipuleucel T 58 progesterone receptor 58 IgG antibodies 58 unresectable stage 58 LHRH 58 Kit CD# positive 58 baseline LDH 58 tumorigenicity 58 IFN gamma 58 PTEN gene 58 KIF6 gene 58 selective inhibitors 58 telomere lengths 58 pre malignant lesions 58 EphA2 58 dexpramipexole 58 leukemic cell 58 lymphoid tissue 58 BRAF V#E 58 retinoic acid receptor 58 plasma kallikrein 58 BRAF inhibitor 58 MLH1 58 PLX# 58 oxysterols 58 molecularly targeted 58 tigecycline 58 HPV subtypes 58 myeloproliferative disorders 58 cranial irradiation 58 PIK3CA 58 immunocompetent 58 SPINK1 58 ritonavir boosted 58 tumor recurrence 58 BRCA2 mutation 58 virologic responses 58 lobular carcinoma 58 ZOLINZA 58 Estrogen Receptor 58 seminomas 58 AMN# [001] 58 MC1R gene 58 p# activation 58 epithelial cancers 58 adjuvant therapies 58 non squamous 58 APOL1 58 Akt1 58 anti androgen 58 raltegravir 58 metastatic cancers 58 mutated BRCA1 58 PTHrP 58 sunitinib 58 erythropoietic 58 clinically localized prostate 58 PKM2 58 genomic alterations 58 mutated p# 58 MMP inhibitors 58 MGd 58 Bevacizumab 58 situ LCIS 58 liposomal doxorubicin 58 hypereosinophilic syndrome 58 gastrointestinal stromal tumor GIST 58 CIMZIA ™ 58 malignant lymphoma 58 COX2 58 Apaziquone 58 PNH patients 58 urine cytology 58 factor receptor 58 eribulin mesylate 58 Alemtuzumab 58 ASCUS 58 tipifarnib 58 histologically 58 hepatic metastases 58 protease inhibitor PI 58 CMV infections 58 exemestane Aromasin 58 ATTR CM 58 HDACi 58 IGFBP 3 58 anaplastic lymphoma kinase 58 candidemia 58 caveolin 1 58 5alpha reductase 58 Sym# 58 heterozygotes 58 VEGF receptor 58 predictive biomarker 58 adenomatous polyps 58 aromatase 58 topoisomerase 58 immunomodulatory therapy 58 BRCA mutation carriers 58 cetuximab Erbitux ® 58 chemotherapeutic regimens 58 cilengitide 58 nonalcoholic steatohepatitis NASH 58 aromatase inhibitor 58 Erbitux cetuximab 58 cervical neoplasia 58 topotecan 58 methylation markers 58 CYC# 58 ZD# [001] 58 elevated triglyceride levels 58 anaplastic lymphoma kinase ALK 58 precursor lesions 58 ovarian tumors 58 IDH mutations 58 docetaxel chemotherapy 58 allogeneic stem cell 58 Malignant Melanoma 58 UGT#A# * 58 GVAX 58 PTEN mutations 58 microdeletions 58 OncoVEX GM CSF 58 immunohistochemical 58 lymph node involvement 58 gastric carcinoma 58 Azixa 57 nucleoside analogues 57 squamous cell lung cancer 57 CYP#B# 57 cervical carcinoma 57 Vorinostat 57 TGFß 57 CCL# 57 systemic fungal infections 57 kinase inhibitors 57 Lenalidomide 57 depsipeptide 57 allogeneic SCT 57 LRP6 57 AEG# 57 activin 57 prostate adenocarcinoma 57 leukemia AML 57 leukemic cells 57 atherosclerotic lesions 57 diagnostic biomarker 57 Crizotinib 57 BARACLUDE ® 57 SGS# 57 Cervista HPV HR 57 metastatic disease 57 homozygotes 57 therapeutic regimens 57 MUC1 * 57 acute myelogenous leukemia AML 57 hTERT 57 estrogen receptor positive 57 clusterin 57 carboplatin paclitaxel 57 histologic subtype 57 thyroglobulin 57 chemotherapeutic agent 57 pancreatic NET 57 ELISpot 57 CDDO Im 57 MEK inhibitors 57 genotypic 57 splice variants 57 malignant neoplasm 57 protein kinase inhibitor 57 antiangiogenic agent 57 antiangiogenic therapy 57 armpit lymph nodes 57 ZNF# 57 IGF1R 57 SMAD4 57 lung metastases 57 histone deacetylase inhibitor 57 TAp# 57 TLR3 57 chemokine receptor 57 neoplasm 57 BAY #-# 57 dacarbazine 57 Virulizin ® 57 HCV infections 57 neoplastic 57 motesanib 57 Hycamtin 57 alvespimycin 57 irinotecan chemotherapy 57 clade B 57 KRAS mutation status 57 breast pancreatic 57 urothelial cancer 57 Gleevec imatinib mesylate 57 thymosin 57 dasatinib Sprycel ® 57 BRCA2 mutations 57 oral prodrug 57 atypical hyperplasia 57 metastatic 57 pancreatic lung 57 IV NSCLC 57 oncoproteins 57 pan HDAC inhibitor 57 glioblastoma 57 ALK mutations 57 NMIBC 57 lymphoid malignancies 57 antitumor effects 57 letrozole Femara 57 Sutent sunitinib 57 undetectable HBV DNA 57 HGS ETR2 57 progesterone receptor negative 57 ductal carcinomas 57 metastases 57 MYDICAR ® 57 type KRAS 57 abiraterone acetate 57 HIF PHI 57 SLNB 57 micafungin 57 Faslodex 57 cardiac toxicity 57 colorectal neoplasia 57 minimally symptomatic 57 standard chemotherapy regimen 57 crizotinib PF # 57 cell lymphoma ALCL 57 PI3K inhibitor 57 choroidal neovascularization 57 elevated CRP 57 metastatic malignant 57 Acute myeloid leukemia 57 autoantibody positive 57 deletion 5q 57 leflunomide 57 APOE ε4 57 germline mutation 57 tumor biopsies 57 galiximab 57 nucleoside analogs 57 ALK inhibitors 57 anticancer therapy 57 MAGE A3 protein 57 benign moles 57 antiandrogens 57 allogeneic HSCT 57 histone deacetylases 57 E#F# 57 BRCA2 gene 57 anti angiogenic therapy 57 N Myc 57 hematologic malignancies 57 BRCA2 mutation carriers 57 platelet aggregation 57 docetaxel Taxotere ® 57 metastatic castration resistant 57 missense mutations 57 adjuvant chemotherapy 57 adenomatous 57 latent tuberculosis infection 57 CD#c 57 Epratuzumab 57 c MYC 57 histologic subtypes 57 chronic HCV 57 vicriviroc 57 CYP#D# 57 Haptoglobin 57 autologous transplants 57 trastuzumab Herceptin R 57 P. falciparum 57 ToGA 57 Mylotarg 57 LHRH receptor positive 57 lupus anticoagulant 57 tubulin inhibitor 57 medulloblastomas 57 anti EGFR antibody 57 cervical lymph nodes 57 HLA B# 57 IL#B 57 OHR/AVR# 57 BRAF inhibitors 57 octreotide LAR 57 vinca alkaloids 57 recurrent genital herpes 57 polycythemia vera PV 57 prostate cancer AIPC 57 bezafibrate 57 bevacizumab 57 BRCA1 gene 57 CagA 57 RANK ligand 57 hormonal therapy 57 anthracycline chemotherapy 57 CDK4 57 refractory multiple myeloma 57 heavily pretreated patients 57 somatostatin analogues 57 myeloid cells 57 HbF 57 untreated metastatic melanoma 57 troponin T 57 sustained virological response 57 prednisone prednisolone 57 homozygous 57 LY# [003] 57 Platinol ® cisplatin 57 TMEM#B 57 prognostic significance 57 cell lymphoma CTCL 57 CD4 + T lymphocytes 57 uterine cancers 57 overexpress 57 invasive candidiasis 57 tumoral 57 bucindolol 57 mTOR mammalian target 57 BRCA2 carriers 57 NS4A 57 TNF blocker therapy 57 eplerenone 57 chemoradiotherapy 57 micronuclei 57 curative resection 57 APTIVUS r 57 p#NTR 57 ErbB3 57 GV# [001] 57 chemotherapy regimens 57 pT2 57 geographic atrophy 57 CCR2 57 rheumatoid factor 57 virotherapy 57 predictive biomarkers 57 pT3 57 canakinumab 57 miRview mets 57 HBV vaccine 57 lymphoid cells 57 milatuzumab 57 neuroendocrine carcinoma 57 squamous cell carcinoma SCC 57 GRNCM1